E-LIB Suche - Ergebnisse für: Bridges, I

1

Evolocumab is initiated in Central and Eastern Europe at Mu..:

Blaha, V ; Margoczy, R ; Petrov, I...
European Cardiology Review. 18 (2023) - p. , 2023

Link: https://doi.org/10.15420..

2

Evolocumab use in Greece is associated with early and susta..:

Vlachopoulos, C. ; Massia, D. ; Kochiadakis, G....
Hellenic Journal of Cardiology. 74 (2023) - p. 74-76 , 2023

Link: https://doi.org/10.1016/..

3

Evolocumab treatment reduces carotid intima-media thickness..:

Wiegman, A ; Ruzza, A ; Hovingh, G K...
European Heart Journal. 43 (2022) Supplement_2 - p. , 2022

Link: https://doi.org/10.1093/..

4

High long-term persistence to evolocumab treatment regimens..:

Ray, K K ; Perrone-Filardi, P ; Ebenbichler, C...
European Heart Journal. 43 (2022) Supplement_2 - p. , 2022

Link: https://doi.org/10.1093/..

5

Evolocumab treatment is associated with early and sustained..:

Ray, K K ; Perrone-Filardi, P ; Ebenbichler, C...
European Heart Journal. 43 (2022) Supplement_2 - p. , 2022

Link: https://doi.org/10.1093/..

6

Final results from the pan-European observational heymans s..:

Ray, K.K. ; Bruckert, E. ; Perrone-Filardi, P....
Atherosclerosis. 355 (2022) - p. 14 , 2022

Link: https://doi.org/10.1016/..

7

Potential cardiovascular risk reduction with evolocumab in ..:

Ray, K ; Bridges, I ; Bruckert, E...
European Heart Journal. 42 (2021) Supplement_1 - p. , 2021

Link: https://doi.org/10.1093/..

8

Evolocumab use and LDL-C lowering in a cohort of european p..:

Sibartie, M. ; Dhalwani, N. ; Bridges, I....
Atherosclerosis. 331 (2021) - p. e253 , 2021

Link: https://doi.org/10.1016/..

9

Effect of evolocumab on cognition in pediatric patients wit..:

Gaudet, D. ; Ruzza, A. ; Bridges, I....
Atherosclerosis. 331 (2021) - p. e258 , 2021

Link: https://doi.org/10.1016/..

10

Evolocumab use in Europe: clinical guidelines vs. reimburse..:

Ray, K K ; Bruckert, E ; Filardi, P...
European Heart Journal. 42 (2021) Supplement_1 - p. , 2021

Link: https://doi.org/10.1093/..

11

What potential risk reduction could be achieved with evoloc..:

Ray, K.K ; Bridges, I ; Bruckert, E...
European Heart Journal. 41 (2020) Supplement_2 - p. , 2020

Link: https://doi.org/10.1093/..

12

Does Evolocumab use in Europe match 2019 ESC/EAS lipid guid..:

Ray, K.K ; Bruckert, E ; Van Hout, B...
European Heart Journal. 41 (2020) Supplement_2 - p. , 2020

Link: https://doi.org/10.1093/..

13

Baseline characteristics of bulgarian patients prescribed e..:

Petkova, R. ; Postadzhiyan, A. ; Petrov, I....
Atherosclerosis. 315 (2020) - p. e212 , 2020

Link: https://doi.org/10.1016/..

14

P654Effectiveness of evolocumab for patients with familial ..:

Ray, K K ; Schoonen, M ; Annemans, L...
European Heart Journal. 40 (2019) Supplement_1 - p. , 2019

Link: https://doi.org/10.1093/..

15

Clinical management of high and very high risk patients wit..:

Petrov, I. ; Dumitrescu, A. ; Ceska, R....
Atherosclerosis. 275 (2018) - p. e237 , 2018

Link: https://doi.org/10.1016/..